These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22162370)

  • 1. Incidence and nature of testicular toxicity findings in pharmaceutical development.
    Sasaki JC; Chapin RE; Hall DG; Breslin W; Moffit J; Saldutti L; Enright B; Seger M; Jarvi K; Hixon M; Mitchard T; Kim JH
    Birth Defects Res B Dev Reprod Toxicol; 2011 Dec; 92(6):511-25. PubMed ID: 22162370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commentary on incidence and nature of testicular toxicity findings in pharmaceutical development survey: a pathologist's perspective.
    Creasy DM
    Birth Defects Res B Dev Reprod Toxicol; 2011 Dec; 92(6):508-10. PubMed ID: 21818841
    [No Abstract]   [Full Text] [Related]  

  • 3. Commentary on "incidence and nature of testicular toxicity findings…".
    Boekelheide K
    Birth Defects Res B Dev Reprod Toxicol; 2011 Dec; 92(6):501-3. PubMed ID: 21948622
    [No Abstract]   [Full Text] [Related]  

  • 4. Whither the resolution of testicular toxicity?
    Birth Defects Res B Dev Reprod Toxicol; 2011 Dec; 92(6):504-7. PubMed ID: 21770029
    [No Abstract]   [Full Text] [Related]  

  • 5. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs.
    Jacobs A
    Toxicol Lett; 2009 Apr; 186(1):32-5. PubMed ID: 18809476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
    Piccini JP; Whellan DJ; Berridge BR; Finkle JK; Pettit SD; Stockbridge N; Valentin JP; Vargas HM; Krucoff MW;
    Am Heart J; 2009 Sep; 158(3):317-26. PubMed ID: 19699852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of drug safety testing: expanding the view and narrowing the focus.
    Stevens JL; Baker TK
    Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status.
    Box RJ; Spielmann H
    Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. State-of-the-art genomics approaches in toxicology.
    Van Hummelen P; Sasaki J
    Mutat Res; 2010 Dec; 705(3):165-71. PubMed ID: 20466069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput human metabolism and toxicity analysis.
    Lee MY; Dordick JS
    Curr Opin Biotechnol; 2006 Dec; 17(6):619-27. PubMed ID: 17046235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
    Powley MW; Frederick CB; Sistare FD; DeGeorge JJ
    Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Juvenile animal toxicity study designs to support pediatric drug development.
    Cappon GD; Bailey GP; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Ooshima Y; Stump DG; Hurtt ME
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):463-9. PubMed ID: 20025047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here?
    Stevens JL
    Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.